The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing [0.03%]
Benjamin A Bleiberg,Dylan G Scholes,Lauren Reed-Guy et al.
Benjamin A Bleiberg et al.
Introduction: Actionable genetic alterations (AGAs) are present in many patients with non-squamous, metastatic non-small cell lung cancer (mNSCLC) and guide the selection of targeted therapies. Guidelines support concurre...
Multi-parametric profiling of plasma-derived extracellular vesicles reveals a disease-associated molecular signature supporting a liquid biopsy approach in myelofibrosis [0.03%]
Ghazal Narimanfar,Husam B R Alabed,Alessia Brancolini et al.
Ghazal Narimanfar et al.
F Salvà,S Pérez Fernandez,C Dopazo et al.
F Salvà et al.
Advances in genomics and liquid biopsy technologies have expanded the understanding of CRLM beyond traditional clinicopathological parameters, enabling real-time disease monitoring and more refined risk stratification.
Large-Scale Quantitative Morphometry of Platelet α-Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy [0.03%]
Yan Ma,Huan Deng,Zelin Liu et al.
Yan Ma et al.
The non-invasive, highly accurate PAID shows great promise in advancing liquid biopsy for cancer management. © 2026 The Author(s). Advanced Science published by Wiley‐VCH GmbH.
Platelets Outperform Leukocytes in Transcriptomic Liquid Biopsy Profiling of Myeloproliferative Neoplasms [0.03%]
Zhu Shen,Abhishek Sawalkar,Jason Wu et al.
Zhu Shen et al.
Myeloproliferative neoplasms (MPNs) are characterized by progressive myelofibrosis that drives morbidity and mortality. Liquid biopsy approaches to noninvasively monitor fibrotic progression remain limited. We performed comparative transcri...
Nida Mubin,Mohammed Alnukhali,Nayab Ahmad et al.
Nida Mubin et al.
Advances in single-cell sequencing, spatial transcriptomics, multiplex imaging, and liquid biopsy technologies, coupled with artificial intelligence-enabled analytics, have enabled high-resolution mapping of heterogeneous tumor immune landscapes and revealed convergent resistance mechanisms driven by
Eleni Kotsiliti
Eleni Kotsiliti
Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience [0.03%]
Oluseyi Abidoye,Angelo Pirozzi,Naohiro Okano et al.
Oluseyi Abidoye et al.
The emergence of personalized liquid biopsy technologies, particularly bespoke circulating tumor DNA (ctDNA), offers new opportunities for improving clinical management. Traditional methods like imaging and tumor markers may miss early recurrence or evolving disease.
PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs [0.03%]
Eltjona Mane,Giulia Cursano,Konstantinos Venetis et al.
Eltjona Mane et al.
Nevertheless, persistent gaps in accreditation, heterogeneous workflows, and limited integration of liquid biopsy highlight ongoing challenges in standardization and diagnostic equity.
Glioblastoma Cells Expressing Oncogenic EGFR Release Multiple Extracellular Vesicle Subpopulations Positive or Negative for EGFR [0.03%]
Elham Pishavar,Fereshteh Shojaei-Ghahrizjani,Brian Meehan et al.
Elham Pishavar et al.
This is especially important in cancer where EVs serve as carriers of unique oncogenic macromolecules that can be transferred to recipient cells or targeted for liquid biopsy diagnostics.
耗时 0.10686 秒，为您在
49668847
条记录里面共找到 6942 篇文章 [XML]